22 May 2013
Keywords: cubist, hit, missed, endpoint, cidecin, trial, pharmaceuticals
Article | 21 January 2002
Cubist Pharmaceuticals reported after the close of the markets onJanuary 16 that the first Phase III trial of its investigational
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 January 2002
21 May 2013
© 2013 thepharmaletter.com